Shares of STAAR Surgical (NASDAQ:STAA – Get Free Report) have earned a consensus rating of “Hold” from the eleven research firms that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $47.00.
Several research analysts recently issued reports on STAA shares. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research report on Wednesday, May 8th. Canaccord Genuity Group cut their target price on STAAR Surgical from $46.00 to $43.00 and set a “hold” rating for the company in a research report on Wednesday, May 8th. BTIG Research raised STAAR Surgical from a “neutral” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Tuesday, June 11th. Mizuho increased their price objective on STAAR Surgical from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $50.00 target price on shares of STAAR Surgical in a research note on Monday, April 1st.
Read Our Latest Analysis on STAA
Institutional Inflows and Outflows
STAAR Surgical Trading Up 7.5 %
STAA opened at $45.51 on Thursday. The stock’s 50 day simple moving average is $42.87 and its 200-day simple moving average is $37.40. The stock has a market cap of $2.24 billion, a PE ratio of 146.81 and a beta of 0.65. STAAR Surgical has a 1 year low of $26.66 and a 1 year high of $58.82.
STAAR Surgical (NASDAQ:STAA – Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.12). STAAR Surgical had a net margin of 4.69% and a return on equity of 6.83%. The business had revenue of $77.40 million during the quarter, compared to the consensus estimate of $75.34 million. During the same period last year, the firm earned $0.05 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. Equities analysts forecast that STAAR Surgical will post 0.08 earnings per share for the current fiscal year.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Featured Articles
- Five stocks we like better than STAAR Surgical
- Airline Stocks – Top Airline Stocks to Buy Now
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- The Most Important Warren Buffett Stock for Investors: His Own
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Financial Services Stocks Investing
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.